

C-3362/0/US

## WHAT IS CLAIMED IS:

1. (Currently amended) A discrete solid pharmaceutical composition consisting essentially of comprising particulate valdecoxib in an amount of about 5 mg to about 40 mg per dose and one or more pharmaceutically acceptable excipients, wherein a single oral administration of the composition in an amount containing about 20 mg of valdecoxib, to a fasting subject provides a time course of blood serum concentration of valdecoxib having a time to reach a concentration of 20 ng/ml not greater than about 0.5 h after administration.
2. (Cancelled)
3. (Previously Presented) The composition of Claim 1 wherein said time course of blood serum concentration of valdecoxib has a time to reach maximum concentration ( $T_{max}$ ) not greater than about 3 h after administration and a maximum concentration ( $C_{max}$ ) not less than about 100 ng/ml.
4. (Cancelled)
5. (Original) The composition of Claim 1 that is a tablet wherein the excipients comprise one or more diluents in an amount of about 5% to about 99%, one or more disintegrants in an amount of about 0.2% to about 30%, one or more binding agents in an amount of about 0.5% to about 25%, and one or more lubricants in an amount of about 0.1% to about 10%, by weight of the composition.
6. (Original) The composition of Claim 5 wherein the binding agent is pregelatinized starch.
7. (Original) The composition of Claim 1 that is a tablet wherein the excipients comprise lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch and magnesium stearate.
8. (Original) The composition of Claim 1 further comprising one or more opioid or analgesic drugs.
9. (Original) The composition of Claim 1 wherein  $D_{90}$  of the valdecoxib particles is less than about 75  $\mu m$ .

C-3362/0/US

10. (Original) The composition of Claim 1 wherein the valdecoxib particles have a weight average particle size of about 1 to about 10  $\mu\text{m}$ .

11-18. (Cancelled)

19. (Previously Presented) A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising orally administering to the subject a composition of Claim 1 one to about four times a day.

20. (Previously Presented) The method of Claim 19, wherein the composition is orally administered to the subject once or twice a day.